CheckMate 214: Efficacy and safety of nivolumab + ipilimumab (N + I) v sunitinib (S) for treatment-naive advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups Meeting Abstract
| Authors: | Escudier, B.; Tannir, N. M.; McDermott, D. F.; Frontera, O. A.; Melichar, B.; Plimack, E. R.; Barthelemy, P.; George, S.; Neiman, V.; Porta, C.; Choueiri, T. K.; Powles, T.; Donskov, F.; Salman, P.; Kollmannsberger, C. K.; Rini, B.; Mekan, S.; McHenry, M. B.; Hammers, H. J.; Motzer, R. J. |
| Abstract Title: | CheckMate 214: Efficacy and safety of nivolumab + ipilimumab (N + I) v sunitinib (S) for treatment-naive advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups |
| Meeting Title: | 42nd ESMO Congress (ESMO 2017) |
| Journal Title: | Annals of Oncology |
| Volume: | 28 |
| Issue: | Suppl. 5 |
| Meeting Dates: | 2017 Sep 8-12 |
| Meeting Location: | Madrid, Spain |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2017-09-01 |
| Start Page: | mdx440.029 |
| Language: | English |
| ACCESSION: | WOS:000411324005089 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdx440.029 |
| Notes: | Meeting Abstract: LBA5 -- Appears on pages 621-622 of the abstract book -- Source: Wos |
